ScreenPoint Medical has raised $16 million to support product development and international expansion of its Transpara breast AI solutions, the company said.
The funding includes $14 million from existing investors Insight Partners and Siemens Healthineers, as well as $2 million in other research grants, according to the firm.
The announcement coincides with several recent research milestones for the platform, ScreenPoint said, including the following:
- Final results from the MASAI randomized controlled trial, published in the Lancet, found Transpara produced favorable outcomes compared with standard double reading, including improvements in cancer detection and workload reduction.
- Prospective research published in Nature Medicine found Transpara could reduce screening mammography workload by up to 63.6% by excluding low-risk mammograms from radiologist review.
- A study in npj Digital Medicine found ScreenPoint's image-based breast cancer risk algorithm outperformed competing solutions at five-year risk prediction, identifying 41.8% of future cancers within the highest 14% of risk scores.
Transpara is in use in more than 30 countries and has processed over 12 million mammograms to date, ScreenPoint noted.
